biotech

Funds management

The listed biotech sector has had a significant sell-off over the past year but innovations still abound, leading investors to ask whether it is time to get back into the...

Funds management

Which has been the strongest short-term theme?

Investors are accused of being ‘theme junkies’ as they chase the latest mega-trend but which theme has seen the strongest returns over the past year?...

Funds management

BioNTech vaccine boosts Platinum fund

The COVID-19 vaccine roll-out may be slow in Australia but exposure to one of its creators has boosted the Platinum European fund after the company’s value doubled to US$...

Funds management

The need for diversification in biotech

Australian investors tend to have a concentrated domestic exposure to biotechnology but may be missing the growth and diversification offered overseas, according to ETF S...

Funds management

Positive forecasts for healthcare stocks in long term

Global healthcare stocks are expected to perform strongly over the long term thanks to a huge boost in healthcare spending across developing and developed economies trigg...

Funds management

The funds set to benefit from vaccine deal

As markets react to the news of a successful COVID-19 vaccine trial from US pharma Pfizer and German biotech firm BioNTech, there are just three funds holding these stock...

Funds management

Platinum benefits from focus on COVID-19 research

Biotechnology is just as exciting as Amazon or Afterpay but often fails to receive the same attention, according to Platinum. ...

Funds management

Pengana boosts healthcare weight to 60%

Pengana has increased its weighting to healthcare in its High Conviction Equities fund as it is confident in the recovery of spending in the sector....

Funds management

Biotech and healthcare funds unable to escape global sell-off

Despite the world rushing to find a vaccine for COVID-19, biotech and healthcare funds have not been able to maintain their former strong returns. ...